Understanding Endothelial Ferroptosis in Vascular Disease

Atherosclerosis remains a predominant driver of cardiovascular morbidity across the globe. Recent investigations demonstrate that endothelial ferroptosis plays an essential role in driving arterial lesion formation. Ferroptosis represents an iron-dependent, non-apoptotic form of regulated cell death defined by severe membrane lipid peroxidation. Consequently, when vascular endothelial cells accumulate toxic lipid reactive oxygen species, endothelial integrity deteriorates rapidly. In addition, this vascular barrier failure accelerates the infiltration of circulating atherogenic lipoproteins into the intimal space. Intracellular iron overload simultaneously fuels Fenton chemistry, thereby generating highly destructive hydroxyl radicals. Furthermore, oxidized low-density lipoprotein triggers endothelial injury and activates programmed inflammatory cascades within the vascular wall. As a result, damaged endothelial cells upregulate adhesion molecules that recruit circulating monocytes. Therefore, targeting endothelial cell survival pathways offers an attractive therapeutic avenue to halt early atherogenesis. Moreover, maintaining an intact endothelial monolayer prevents early lipid entrapment and vascular calcification. Thus, scientists increasingly investigate novel molecular pathways that protect the endothelial lining from ferroptotic death. Consequently, understanding how natural molecules modulate iron homeostasis is vital for future vascular interventions.

Biological Profile of Protosappanin A and Caesalpinia sappan

Botanical compounds provide valuable scaffolds for modern drug discovery. Caesalpinia sappan L., widely recognized in traditional Indian and Asian medicine, contains diverse bioactive dibenzoxocins. Among these constituents, Protosappanin A represents a prominent water-soluble monomer possessing remarkable biological activities. Additionally, modern analytical techniques have characterized the precise molecular structure and chemical purity of this compound. Historically, traditional practitioners utilized Sappan wood extracts to enhance blood circulation, alleviate swelling, and treat cardiovascular complaints. In modern pharmacology, Protosappanin A demonstrates profound antioxidant, anti-inflammatory, and immunomodulatory properties in preclinical models. Furthermore, researchers have documented its ability to scavenge free radicals and preserve cellular organelle architecture. Recent studies indicate that Protosappanin A prevents mitochondrial dysfunction during periods of acute oxidative stress. In addition, the compound readily enters vascular tissues and stabilizes cellular membranes without causing cytotoxicity. Because atherosclerosis involves chronic oxidative stress, natural polyphenols like Protosappanin A attract substantial scientific attention. Moreover, researchers want to establish whether this natural product acts through distinct mechanistic targets rather than generalized antioxidant scavenging. Therefore, investigators recently designed rigorous experiments to delineate the exact cellular signaling cascades governed by Protosappanin A.

Preclinical Findings: Plaque Regression and Endothelial Integrity

To test therapeutic efficacy, researchers evaluated Protosappanin A in apolipoprotein E-deficient mice fed an atherogenic high-fat diet. The team administered either Protosappanin A or simvastatin daily for twelve consecutive weeks. Notably, Protosappanin A markedly reduced total aortic plaque surface area on en face Oil Red O staining. Histological evaluations confirmed substantial reductions in intimal lesion thickness across the aortic arch. Furthermore, Protosappanin A significantly improved circulating lipid profiles in treated animals. The intervention produced sharp decreases in serum triglycerides, total cholesterol, and low-density lipoprotein cholesterol while elevating protective high-density lipoprotein. Beyond systemic lipid modulation, the compound directly attenuated vascular endothelial injury. Specifically, aortic tissues displayed significantly reduced expression of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1. As a result, monocyte adhesion and macrophage infiltration into the subendothelial space declined dramatically. In contrast to untreated controls, animals receiving Protosappanin A maintained continuous endothelial monolayer architecture. Consequently, these multi-faceted outcomes demonstrate that Protosappanin A retards atheroma progression while exerting robust vascular protective actions.

Mechanistic Elucidation of the MDM2 and GPX4 Axis

To uncover the precise molecular mechanism, investigators performed comprehensive RNA sequencing on oxidized low-density lipoprotein-treated human umbilical vein endothelial cells. By integrating transcriptomic datasets with ferroptosis databases, they identified mouse double minute 2 homolog as a primary target. Mechanistically, oxidized lipoproteins induce excessive MDM2 expression, which downregulates glutathione peroxidase 4. GPX4 functions as the master enzymatic guardian against ferroptosis by reducing toxic phospholipid hydroperoxides to non-toxic lipid alcohols. When MDM2 suppresses GPX4, intracellular ferrous iron accumulates and initiates massive lipid reactive oxygen species production. However, Protosappanin A administration effectively represses aberrant MDM2 upregulation in endothelial cells. Consequently, Protosappanin A restores intracellular GPX4 levels alongside system xc- cystine/glutamate antiporter and ferritin heavy chain 1. This coordinated restoration lowers intracellular malondialdehyde and curbs mitochondrial swelling and outer membrane rupture. Furthermore, immunofluorescence staining confirmed strong GPX4 re-expression within the aortic endothelium. To confirm this pathway, researchers overexpressed MDM2 in validation assays. Remarkably, MDM2 overexpression reactivated endothelial ferroptotic cascades and abolished the protective benefits of Protosappanin A. Thus, the experimental evidence definitively confirms that Protosappanin A suppresses endothelial ferroptosis via the MDM2/GPX4 regulatory axis.

Translational Relevance for Clinical Practice in India

Cardiovascular diseases account for more than a quarter of all mortality across India, often affecting individuals at younger ages. Indian patients frequently exhibit an atherogenic phenotype characterized by elevated triglycerides, low HDL cholesterol, and dense LDL particles. Although guideline-directed statin therapies reduce adverse cardiovascular events, residual atherogenic risk remains substantial among South Asian populations. Therefore, discovering complementary therapeutic strategies that target non-traditional pathways, such as vascular ferroptosis, carries immense clinical relevance. Caesalpinia sappan, known in Ayurveda as Patanga, has occupied a central place in classical Indian formulations like Patangassavam for centuries. Traditionally, Ayurvedic practitioners prescribe Patanga for bleeding disorders, inflammatory conditions, and metabolic imbalances. The scientific validation of Protosappanin A provides a robust pharmacological foundation for these ancient applications. Furthermore, identifying MDM2 and GPX4 as druggable targets invites the synthesis of standardized phytochemical formulations or novel synthetic derivatives. Integrating molecularly validated botanicals into preventive cardiology could potentially optimize endothelial health and slow disease progression. However, clinicians must remember that current evidence derives predominantly from preclinical models. Consequently, rigorous human clinical trials evaluating bioavailability, optimal dosing, and long-term safety must precede any clinical implementation in routine patient care.

What is the therapeutic significance of targeting endothelial ferroptosis in atherosclerosis?

Atherosclerosis involves chronic arterial inflammation and lipid accumulation, but endothelial cell loss accelerates plaque instability. Ferroptosis specifically promotes endothelial cell death through iron-dependent lipid peroxidation. By inhibiting endothelial ferroptosis, clinicians can preserve the structural integrity of the vascular lining, reduce inflammatory cell infiltration, and prevent necrotic core enlargement. Consequently, targeting ferroptotic signaling pathways provides an innovative cardioprotective mechanism that complements traditional lipid-lowering therapies to prevent clinical ischemic cardiovascular events.

How does the MDM2/GPX4 molecular axis regulate ferroptotic endothelial death?

Mouse double minute 2 homolog acts as a critical negative regulator of glutathione peroxidase 4. In atherogenic conditions, oxidized lipoproteins stimulate MDM2 expression, which consequently triggers GPX4 degradation. Because GPX4 eliminates toxic lipid hydroperoxides, its loss allows unrestrained accumulation of toxic reactive oxygen species and ferrous iron. Protosappanin A suppresses MDM2 expression, thereby restoring GPX4 levels. In addition, it shields endothelial cells from lethal membrane lipid peroxidation during sustained metabolic and oxidative stress.

Can Protosappanin A or Caesalpinia sappan replace statins in cardiovascular therapy?

Protosappanin A cannot currently replace statins in clinical practice. Although animal studies show robust anti-atherosclerotic effects comparable to simvastatin, researchers have not yet conducted human trials. Guideline-directed statins possess decades of robust randomized trial evidence for cardiovascular mortality reduction. Therefore, Caesalpinia sappan extracts and isolated Protosappanin A remain investigational agents. In addition, they may eventually serve as adjunctive therapies rather than immediate substitutes for established pharmacotherapy.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Fu J et al. Protosappanin A Alleviates Atherosclerosis by Regulating the MDM2/GPX4 Axis-Mediated Endothelial Ferroptosis. Phytother Res. 2026 Sep 08. doi: 10.1002/ptr.70443. PMID: 42711266.


2. Rafieian-Kopaei M, et al. Antioxidants and Atherosclerosis: Mechanistic Aspects. Biomolecules. 2019;9(8):301. doi: 10.3390/biom9080301. PMID: 31349600.


3. Stockwell BR. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185(14):2401-2421. doi: 10.1016/j.cell.2022.06.003. PMID: 35803244.